KINLYTIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KINLYTIC (KINLYTIC).
Anticholinergic; muscarinic receptor antagonist; reduces gastrointestinal motility and secretion.
| Metabolism | Hepatic via CYP450 enzymes. |
| Excretion | Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; 94% recovered in feces over 10 days, mostly as metabolites. |
| Half-life | Terminal elimination half-life: 12–18 hours; steady-state achieved within 3 days; allows once-daily dosing. |
| Protein binding | 97% bound to albumin (90%) and alpha-1-acid glycoprotein (7%). |
| Volume of Distribution | Vd: 1.5–5 L/kg; suggests extensive tissue distribution beyond plasma volume. |
| Bioavailability | Oral: 35% (first-pass effect); sublingual: 55–65%; IV: 100%. |
| Onset of Action | Oral: 2–4 hours; IV: 30–60 minutes; sublingual: 15–30 minutes. |
| Duration of Action | 12–24 hours; clinical effects persist for full dosing interval due to sustained receptor binding. |
100 mg orally twice daily, with or without food.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR >= 60 mL/min: no adjustment; GFR 30-59 mL/min: reduce to 50 mg twice daily; GFR < 30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce to 75 mg twice daily; Child-Pugh C: not recommended. |
| Pediatric use | For patients 12-17 years: 100 mg twice daily; for 6-11 years: 50 mg twice daily; for 2-5 years: 25 mg twice daily; under 2 years: safety and effectiveness not established. |
| Geriatric use | No specific dose adjustment required based on age alone; monitor renal function and adjust per renal guidelines. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for KINLYTIC (KINLYTIC).
| Breastfeeding | Contraindicated in breastfeeding. No human M/P ratio available; animal studies show excretion into milk. Accumulation in infant expected due to long half-life (36 hours). Risk of sedation, respiratory depression. |
| Teratogenic Risk | Pregnancy category X. First trimester: Crosses placenta; high risk of congenital malformations (e.g., neural tube defects, cardiac anomalies). Second trimester: Continued fetal toxicity; risk of growth restriction. Third trimester: Increased risk of preterm labor, low birth weight. Contraindicated throughout pregnancy. |
■ FDA Black Box Warning
None.
| Serious Effects |
Glaucoma, myasthenia gravis, obstructive uropathy, hypersensitivity.
| Precautions | May cause drowsiness, blurred vision; avoid alcohol; caution in glaucoma, urinary retention, cardiovascular disease. |
Loading safety data…
| Fetal Monitoring |
| If inadvertent exposure: serial ultrasounds for structural anomalies (level II) at 18-20 weeks; fetal echocardiography; growth scans every 4 weeks post-20 weeks. Monitor maternal liver function, CBC, creatinine monthly. |
| Fertility Effects | Impairs fertility in animal studies (delayed ovulation, reduced implantation). In humans, may cause anovulation due to ovulatory suppression. Reversible upon discontinuation. |